CN116963736A - 马赛替尼用于治疗阿尔茨海默病 - Google Patents
马赛替尼用于治疗阿尔茨海默病 Download PDFInfo
- Publication number
- CN116963736A CN116963736A CN202180093808.7A CN202180093808A CN116963736A CN 116963736 A CN116963736 A CN 116963736A CN 202180093808 A CN202180093808 A CN 202180093808A CN 116963736 A CN116963736 A CN 116963736A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- treatment
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306589 | 2020-12-16 | ||
| EP20306589.1 | 2020-12-16 | ||
| PCT/EP2021/086308 WO2022129410A1 (en) | 2020-12-16 | 2021-12-16 | Masitinib for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116963736A true CN116963736A (zh) | 2023-10-27 |
Family
ID=74141317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180093808.7A Pending CN116963736A (zh) | 2020-12-16 | 2021-12-16 | 马赛替尼用于治疗阿尔茨海默病 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058328A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4262801A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023554354A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230125804A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116963736A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021399925A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201259A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303521A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007029A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022129410A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| AR080380A1 (es) * | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
-
2021
- 2021-12-16 US US18/256,721 patent/US20240058328A1/en active Pending
- 2021-12-16 KR KR1020237023563A patent/KR20230125804A/ko active Pending
- 2021-12-16 CA CA3201259A patent/CA3201259A1/en active Pending
- 2021-12-16 JP JP2023536086A patent/JP2023554354A/ja active Pending
- 2021-12-16 CN CN202180093808.7A patent/CN116963736A/zh active Pending
- 2021-12-16 AU AU2021399925A patent/AU2021399925A1/en active Pending
- 2021-12-16 MX MX2023007029A patent/MX2023007029A/es unknown
- 2021-12-16 EP EP21839188.6A patent/EP4262801A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086308 patent/WO2022129410A1/en not_active Ceased
- 2021-12-16 IL IL303521A patent/IL303521A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| PIETTE等: "Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial", 《ALZHEIMER’S RESEARCH & THERAPY》, vol. 3, no. 2, 19 April 2011 (2011-04-19), pages 1 - 11, XP021102296, DOI: 10.1186/alzrt75 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022129410A1 (en) | 2022-06-23 |
| EP4262801A1 (en) | 2023-10-25 |
| KR20230125804A (ko) | 2023-08-29 |
| AU2021399925A1 (en) | 2023-06-29 |
| JP2023554354A (ja) | 2023-12-27 |
| US20240058328A1 (en) | 2024-02-22 |
| IL303521A (en) | 2023-08-01 |
| MX2023007029A (es) | 2023-07-18 |
| CA3201259A1 (en) | 2022-06-23 |
| AU2021399925A9 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108883108B (zh) | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 | |
| WO2009017455A1 (en) | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor | |
| US20180311236A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
| JP7731868B2 (ja) | TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法 | |
| US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
| JP7788154B2 (ja) | 多発性硬化症患者の亜集団の処置のためのマシチニブ | |
| US8513280B2 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
| JP2025176192A (ja) | 好酸球性喘息の処置のためのmasitinibの使用 | |
| JP2023554354A (ja) | アルツハイマー病の処置のためのマシチニブ | |
| CZ27299A3 (cs) | Způsob léčení bipolární afektivní poruchy | |
| WO2008069726A1 (en) | Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes | |
| CN117337177A (zh) | 马赛替尼用于治疗去势抵抗性前列腺癌 | |
| EP0821958A2 (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression | |
| HK1261581B (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| WO2022060978A1 (en) | Methods of treating parkinson's disease and related disorders with pde10a inhibitors | |
| HK1008931A (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline ) for treating excessive aggression | |
| HK1008932A (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol -3-yl)-1,2,5,6,-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |